From: Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5
Primary tissue | Unique mutated samples | % mutated | Total unique samples | Mutation data | references |
---|---|---|---|---|---|
bilary tract | 0 | 0% | 2 | Â | Â |
breast | 0 | 0% | 201 | Â | Â |
CNS | 0 | 0% | 477 | Â | Â |
haematopoietic and lymphoid tissue | 0 | 0% | 27 | Â | Â |
kidney | 0 | 0% | 28 | Â | Â |
large intestine | 0 | 0% | 42 | Â | Â |
lung | 2 | 1% | 171 | c.406 C > T: L136L | [49] |
c.450 G > A: K150K | [49] | ||||
c.1371A > G: E457E | [49] | ||||
melanoma | 1 | 4% | 25 | c.890 G > A: L297E | [54] |
ovary | 1 | 1% | 85 | c.660 + 2 T > A: intronic mutation | [50] |
pancreas | 0 | 0% | 31 | Â | Â |
pleura | 0 | 0% | 1 | Â | Â |
prostate | 0 | 0% | 58 | Â | Â |
salivary gland | 0 | 0% | 9 | Â | Â |
skin | 0 | 0% | 6 | Â | Â |
stomach | 0 | 0% | 34 | Â | Â |
testis | 0 | 0% | 13 | Â | Â |
upper aerodigestive tract | 0 | 0% | 19 | Â | Â |
urinary tract | 0 | 0% | 2 | Â | Â |